MacroGenics
MGNX
HK$12.40
Share price
-5.39%
Change (1 day)
-70.98%
Change (1 year)
Categories
Revenue for MacroGenics (MGNX)
Revenue in 2025 (TTM): HK$1.18 Billion
According to MacroGenics's latest financial reports the company's current revenue (TTM 
) is HK$1.19 Billion. In 2024 the company made a revenue of HK$1.15 Billion an increase over the revenue in the year 2023 that were of HK$0.44 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for MacroGenics from 2013 to 2025
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2025 (TTM) | HK$1.18 B | 2.92% |
| 2024 | HK$1.15 B | 157.82% |
| 2023 | HK$0.44 B | -61.78% |
| 2022 | HK$1.16 B | 96.93% |
| 2021 | HK$0.59 B | -21.69% |
| 2020 | HK$0.75 B | 56.9% |
| 2019 | HK$0.48 B | 2.6% |
| 2018 | HK$0.47 B | -61.8% |
| 2017 | HK$1.23 B | 72.98% |
| 2016 | HK$0.71 B | -8.85% |
| 2015 | HK$0.78 B | 113.23% |
| 2014 | HK$0.36 B | -16.7% |
| 2013 | HK$0.44 B |
Revenue for similar companies or competitors
| Company | Revenue | Revenue differencediff. | Country |
|---|---|---|---|
 Xencor XNCR | HK$1.13 B | -5.23% | 🇺🇸 USA |
 Pfizer PFE | HK$490.29 B | 40,878.96% | 🇺🇸 USA |
 Merck MRK | HK$501.74 B | 41,836.14% | 🇺🇸 USA |
 Gilead Sciences GILD | HK$225.54 B | 18,750.99% | 🇺🇸 USA |
 Amgen AMGN | HK$267.86 B | 22,288.42% | 🇺🇸 USA |
 Eli Lilly LLY | HK$384.64 B | 32,048.64% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | HK$373.90 B | 31,151.68% | 🇺🇸 USA |